Together with the parental U-87 MG (ATCC® HTB-14™) cells, ATCC® HTB-14IG ™ provides an ideal model for studying tumor-associated IDH1 mutation and its impact during cellular metabolism and epigenetic regulation. In addition this parental and isogenic pair serve as an ideal screening tool for IDH1-specific inhibitors as well as anti-cancer drug discovery and development.
IDH1 and IDH2 mutations are seen in glioma and acute myeloid leukemia as well as in many human cancers. These are cancer driver genes that cause a gain-of-function in tumor cells. IDH is a metabolic enzyme that interconverts isocitrate and alpha-ketoglutatrate in the TCA cycle. Cancer-associated point mutations seen in IDH1 and IDH2 confer neomorphic activity resulting in the reduction alpha-KG to the oncometabolite 2-hydroxyglutarate or 2-HG. High concentrations of 2HG have been shown to inhibit alphaKG-dependent dioxygenases, including histone and DNA demethylases, which alter epigenetic regulation, leading to cellular differentiation and tumorigenesis.
|Date Created||10/03/2017 11:58 AM
|Date Updated||10/03/2017 11:58 AM